Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
CEO and President David Brand to Leave Cardiokine
October 5th, 2007
Cardiokine, Inc., a privately held specialty pharmaceutical company focused on the development of drugs for the treatment of heart failure and related indications, announced that President and Chief Executive Officer David Brand will be leaving the company. "We are grateful for David's many contributions to Cardiokine, which include building the current development team, successfully completing a $50 million Series B financing and most recently, securing a global co-development and commercialization agreement for Lixivaptan with Biogen Idec. We wish him continued success in the future," said James H. Cavanaugh, Ph.D., Chairman of Cardiokine's Board of Directors. ...
Source: Health Business Week (2007-10-05)
|
